HIV Associated Neurocognitive Disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: A cross sectional study

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Kelly, Christine M ^a,b   Van Oosterhout, Joep J ^b,d   Ngwalo, Chisomo ^b   Stewart, Robert C ^b   Benjamin, Laura ^a   Robertson, Kevin R ^c   Khoo, Saye ^a   Allain, Theresa J ^b   Solomon, Tom ^a,e,f  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF MALAWI   (Malawi)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d DIGNITAS INTERNATIONAL   (Malawi)

^e THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

^f NIHR Health Protection Research Unit in Emerging and Zoonotic Infections   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; NEVIRAPINE;

ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; ETHNIC GROUP; FEMALE; FRASCATI CRITERIA; GLOBAL DEFICIT SCORE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALAWIAN; MALE; MEDICATION COMPLIANCE; MILD COGNITIVE IMPAIRMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; PREVALENCE; RISK FACTOR; SCORING SYSTEM; ADOLESCENT; COGNITION DISORDERS; COMPLICATION; CROSS-SECTIONAL STUDY; HIV INFECTIONS; MALAWI; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALAWI; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREVALENCE; RISK FACTORS; YOUNG ADULT;

EID: 84902573941     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098962     Document Type: Article

References (45)

1. Garvey L, Surendrakumar V, Winston A (2011) Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy. HIV Clin Trials 12: 333-338.
2. Kim DH, Jewison DL, Milner GR, Rourke SB, Gill MJ, et al. (2001) Neurocognitive symptoms and impairment in an HIV community clinic. Can J Neurol Sci 28: 228-231. (Pubitemid 32785927)
3. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, et al. (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75: 2087-2096.
4. Patel VN, Mungwira RG, Tarumbiswa TF, Heikinheimo T, van Oosterhout JJ (2010) High prevalence of suspected HIV-associated dementia in adult Malawian HIV patients. Int J STD AIDS 21: 356-358.
5. Lawler K, Jeremiah K, Mosepele M, Ratcliffe SJ, Cherry C, et al. (2011) Neurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana. PLoS One 6: e17233.
6. Robbins RN, Remien RH, Mellins CA, Joska JA, Stein DJ (2011) Screening for HIV-associated dementia in South Africa: potentials and pitfalls of task-shifting. AIDS Patient Care STDS 25: 587-593.
7. Njamnshi AK, Djientcheu Vde P, Fonsah JY, Yepnjio FN, Njamnshi DM, et al. (2008) The International HIV Dementia Scale is a useful screening tool for HIV-associated dementia/cognitive impairment in HIV-infected adults in Yaounde-Cameroon. J Acquir Immune Defic Syndr 49: 393-397.
8. Joska JA, Westgarth-Taylor J, Hoare J, Thomas KG, Paul R, et al. (2011) Validity of the International HIV Dementia Scale in South Africa. AIDS Patient Care STDS 25: 95-101.
9. Lawler K, Mosepele M, Ratcliffe S, Seloilwe E, Steele K, et al. (2010) Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study. J Int AIDS Soc 13: 15.
10. Sacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnes OA, et al. (2005) The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 19: 1367-1374. (Pubitemid 41800672)
11. Oshinaike OO, Akinbami AA, Ojo OO, Ojini IF, Okubadejo UN, et al. (2012) Comparison of the Minimental State Examination Scale and the International HIV Dementia Scale in Assessing Cognitive Function in Nigerian HIV Patients on Antiretroviral Therapy. AIDS Res Treat 2012: 581531.
12. Wong MH, Robertson K, Nakasujja N, Skolasky R, Musisi S, et al. (2007) Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology 68: 350-355. (Pubitemid 46184210)
13. Nakku J, Kinyanda E, Hoskins S (2013) Prevalence and factors associated with probable HIV dementia in an African population: A cross-sectional study of an HIV/AIDS clinic population. BMC Psychiatry 13: 126.
14. Parsons TD, Braaten AJ, Hall CD, Robertson KR (2006) Better quality of life with neuropsychological improvement on HAART. Health Qual Life Outcomes 4: 11.
15. Rodriguez-Penney AT, Iudicello JE, Riggs PK, Doyle K, Ellis RJ, et al. (2013) Co-Morbidities in Persons Infected with HIV: Increased Burden with Older Age and Negative Effects on Health-Related Quality of Life. AIDS Patient Care STDS 27: 5-16.
16. Rueda S, Raboud J, Mustard C, Bayoumi A, Lavis JN, et al. (2011) Employment status is associated with both physical and mental health quality of life in people living with HIV. AIDS Care 23: 435-443.
17. Tozzi V, Balestra P, Murri R, Galgani S, Bellagamba R, et al. (2004) Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. Int J STD AIDS 15: 254-259. (Pubitemid 38570132)
18. Scott JC, Woods SP, Vigil O, Heaton RK, Schweinsburg BC, et al. (2011) A neuropsychological investigation of multitasking in HIV infection: implications for everyday functioning. Neuropsychology 25: 511-519.
19. Ettenhofer ML, Hinkin CH, Castellon SA, Durvasula R, Ullman J, et al. (2009) Aging, neurocognition, andmedication adherence in HIV infection. Am JGeriatr Psychiatry 17: 281-290.
20. Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, Lam MN, et al. (2002) Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology 59: 1944-1950. (Pubitemid 36076569)
21. Selnes OA (2002) Neurocognitive aspects of medication adherence in HIV infection. J Acquir Immune Defic Syndr 31 Suppl 3: S132-135.
22. Robertson K, Kumwenda J, Supparatpinyo K, Jiang JH, Evans S, et al. (2011) A multinational study of neurological performance in antiretroviral therapy-naive HIV-1-infected persons in diverse resource-constrained settings. J Neurovirol 17: 438-447.
23. Ho DD, Rota TR, Schooley RT, Kaplan JC, Allan JD, et al. (1985) Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med 313: 1493-1497. (Pubitemid 16182477)
24. McArthur JC, Brew BJ (2010) HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS 24: 1367-1370.
25. Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, et al. (2010) Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 75: 864-873.
26. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, et al. (2004) Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 26: 307-319. (Pubitemid 39277061)
27. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, et al. (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69: 1789-1799. (Pubitemid 350059308)
28. Haddow LJ, Floyd S, Copas A, Gilson RJ (2013) A systematic review of the screening accuracy of the HIV Dementia Scale and International HIV Dementia Scale. PLoS One 8: e61826.
29. Robertson K, Liner J, Heaton R (2009) Neuropsychological assessment of HIV-infected populations in international settings. Neuropsychol Rev 19: 232-249.
30. Karnofsky D, Burchenal J (1949) The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In: CM M, editor. Evaluation of Chemotherapeutic Agents: Columbia Univ Press. pp. 196.
31. Stewart RC, Kauye F, Umar E, Vokhiwa M, Bunn J, et al. (2009) Validation of a Chichewa version of the self-reporting questionnaire (SRQ) as a brief screening measure for maternal depressive disorder in Malawi, Africa. J Affect Disord 112: 126-134.
32. Else L, Watson V, Tjia J, Hughes A, Siccardi M, et al. (2010) Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci 878: 1455-1465.
33. http://www.hiv-druginteractions.org/FactSheets.aspx In: Liverpool Uo, editor.
34. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, et al. (2009) Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42: 377-381.
35. Abers MS, Shandera WX, Kass JS (2014) Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs 28: 131-145.
36. Gutierrez F, Navarro A, Padilla S, Anton R, Masia M, et al. (2005) Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 41: 1648-1653. (Pubitemid 41691605)
37. Nanzigu S, Eriksen J, Makumbi F, Lanke S, Mahindi M, et al. (2012) Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans. HIV Med 13: 193-201.
38. Robertson KR, Nakasujja N, Wong M, Musisi S, Katabira E, et al. (2007) Pattern of neuropsychological performance among HIV positive patients in Uganda. BMC Neurol 7: 8.
39. Nakasujja N, Skolasky RL, Musisi S, Allebeck P, Robertson K, et al. (2010) Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC Psychiatry 10: 44.
40. Gisslen M, Price RW, Nilsson S (2011) The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis 11: 356.
41. Braganca M, Palha A (2011) Depression and neurocognitive performance in Portuguese patients infected with HIV. AIDS Behav 15: 1879-1887.
42. Fernandes Filho SM, de Melo HR (2012) Frequency and risk factors for HIV-associated neurocognitive disorder and depression in older individuals with HIV in northeastern Brazil. Int Psychogeriatr 24: 1648-1655.
43. Deeks SG, Tracy R, Douek DC (2013) Systemic effects of inflammation on health during chronic HIV infection. Immunity 39: 633-645.
44. Bonnet F, Amieva H, Marquant F, Bernard C, Bruyand M, et al. (2013) Cognitive disorders in HIV-infected patients: are they HIV-related? AIDS 27: 391-400.
45. Fabbiani M, Ciccarelli N, Tana M, Farina S, Baldonero E, et al. (2013) Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients. HIV Med 14: 136-144.